Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, I'm one the senior biotech analysts here at JPMorgan. I'm pleased to welcome our next presenting company, Rigel Pharmaceuticals. And presenting on behalf of the company, we have CEO, Raul Rodriguez. Before I'd -- I'd like to hand it over to Raul to start his presentation.
Thank you, Tessa. I appreciate it, and thank you, everyone, for attending the conference. It's nice to be able to present to you this day. First, let me start with an important forward-looking statement that pertains to this presentation. You can review this statement on our website as well as our filings at the SEC.
Let me start on Slide 3. In 2021, we made important progress across all the key value drivers for Rigel, that you see here on this slide. And what this does, is set us up with what we believe will be a transformative year for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |